Recurrence Rate of Small Melanoma In Situ on Low-Risk Sites Excised With 5-mm Excisional Margin
How much is enough? Exploring excisional margins for in situ melanoma When a patient with melanoma in situ has a…
Recurrence Rate of Small Melanoma In Situ on Low-Risk Sites Excised With 5-mm Excisional Margin
How much is enough? Exploring excisional margins for in situ melanoma When a patient with melanoma in situ has a…
,
Turn Hope into Action with AIM at Melanoma
…everyone affected by melanoma. DONATE TODAY! Stay Informed: Access the latest research and treatment options that enhance the fight against…
,
Empowering Women in Melanoma: A Look Inside the Women in Melanoma Initiative
In 2016, the late Valerie Guild—founder and then-president of AIM at Melanoma—attended a melanoma conference and noticed something striking: While…
From the Clinic to the Living Room: Conversations with Melissa Wilson, PA-C, MPAS
…Melanoma Need to Know. Melissa discussed the disease as it relates to melanoma patients and helped listeners understand terms like…
What is Translational Medicine?
…medicine in melanoma? Recent progress in melanoma drug development highlights the critical impact that translational medicine plays in advancing the…
,
In One Woman’s Memory, a Tradition Helps Create a Community of Support
…misdiagnosed with breast cancer and underwent chemotherapy and a mastectomy before doctors realized her cancer was actually melanoma. Tricia was…
,
,
AIM Launches Peer to Peer Mentoring Program
AIM at Melanoma is pleased to announce Peer Connect, a peer-to-peer mentoring program for anyone touched by melanoma. Here’s how…
Melanoma by the State: Utah
…So High in Utah? Besides being a state with a majority of white residents whose fair skin is a risk for melanoma,…
,
The Conversation Has Changed For Stage III Melanoma
…conversations, read our recent In Plain English article, as well as our online guide called Options for Stage III Melanoma:…
,
Melanoma By The State: Vermont
…it has a high incidence of melanoma. Vermont has the nation’s second-highest per-capita rate of new melanoma cases. According to…
,
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026